ABSTRACT
Background A major concern in emergency departments is whether acute respiratory illness (ARI) is associated with increased risk of venous thromboembolism (VTE).
Methods This prospective cohort study includes ARI patients from the 91-hospital, U.S. CDC- sponsored Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS) program from January 2022 to June 2023. We calculated incidence rates and used multivariable regression models to test the null hypothesis that there is no association between the results or absence of laboratory viral testing and the risk of new onset VTE within 30-days.
Findings Out of 620,303 ARI encounters, 65% underwent laboratory viral testing; 13% tested positive for COVID and 3%-4% tested positive for influenza-A and/or RSV. The 30-day VTE incidence rate was 0.70% among unique first patient encounters and 0.82% overall.
The highest VTE incidence rate occurred among viral test negative patient encounters (1.13% [95%CI 1.08%-1.19%]) and the lowest VTE rate occurred among patients who tested positive for COVID, influenza-A or RSV, or who did not undergo viral testing (95%CI 0.09%-0.86%). In adjusted models, only among patients receiving any ICU care was fluA associated with heightened VTE risk.
New VTE was associated with increased 30-day mortality risk (RR 2.7, 95%CI 2.3-3.2), but there was no difference in 30-day mortality risk among VTE patients grouped by the results of viral testing (interaction p > 0.05).
Conclusion In the U.S. from January 2022 to June 2023, laboratory confirmed viral infection was not associated with increased risk of short-term VTE diagnosis or death among patients seeking emergency care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funded by contract 75D30121C11813 and named the Respiratory Virus Laboratory Emergency Department Network Surveillance (RESP-LENS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Briefly, RESP-LENS involves the collaboration of 24 investigators representing 91 hospitals and the CDC who prospectively surveil viral infections (https://www.cdc.gov/surveillance/resp-lens/dashboard.html). The network began in September 2021, and 22 of 24 sites, covering all ten U.S. Department of Health and Human Services regions, were reporting data as of January 2022 (Supplemental Table 1). The protocol was reviewed by all site institutional review boards and was either deemed non-human subjects research (i.e., surveillance), exempted from review or approved with expedited review. Importantly, RESP-LENS adheres to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) and RECORD (Reporting of studies Conducted using Observational Routinely-collected Data) reporting guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The RESP-LENS data management and data sharing plans are publicly available at https://dmptool.org/plans/70148.
